ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1931

Health System Improvement in Appropriate Test Utilization Involving ANA Testing in the Inpatient and Outpatient Setting
Abstract Number: 1932

Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology
Abstract Number: 1933

Telemedicine for Under-resourced Patients with Systemic Lupus Erythematosus: A Qualitative Study Exploring the Views and Experiences of Patients and Rheumatology Health Care Professionals
Abstract Number: 1934

Knee Symptom Phenotyping Incorporating Pain and Function: A Multiple-Trajectory Modeling-Based Study Using Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 1935

Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Abstract Number: 1936

Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries
Abstract Number: 1937

Wellness and Burnout Among Pediatric Rheumatologists in North America- A 2024 CARRA Study
Abstract Number: 1938

Evaluating Diagnostic Performance of Mycobacterium Tuberculosis Derived Cell-free DNA (CF-DNA) for Diagnosis of Osteoarticular Tuberculosis (OATB): A Novel Method
Abstract Number: 1939

Patient’s Satisfaction with a Telerheumatology Program in a Remote Rural Area of Northern Pakistan
Abstract Number: 1940

Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative
Abstract Number: 1941

No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders
Abstract Number: 1942

Electronic Health Literacy and Its Association with Disease Activity in RMD Patients – a Cross Sectional Study
Abstract Number: 1943

Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis
Abstract Number: 1944

Enhancing Rheumatology Consultations with AI-Powered Triage: The ReumAI Pilot Study
Abstract Number: 1945

The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].